{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:58:21Z","timestamp":1791806301712,"version":"4.3.4"},"reference-count":93,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T00:00:00Z","timestamp":1277424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The absence of specific histological or serological markers, the gaps in understanding the aetiology and pathophysiology of rosacea, and the broad diversity in its clinical manifestations has made it difficult to reach international consensus on therapy guidelines.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> The main objective was to highlight the global diversity in current thinking about rosacea pathophysiology, classification and medical features, under particular consideration of the relevance of the findings to optimization of therapy.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> The article presents findings, proposals and conclusions reached by the ROSacea International Expert group (ROSIE), comprising European and US rosacea experts.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> New findings on pathogenesis provide a rationale for the development of novel therapies. Thus, recent findings suggest a central role of the antimicrobial peptide cathelicidin and its activator kallikrein\u20105 by eliciting an exacerbated response of the innate immune system. Cathelicidin\/kallikrein\u20105 also provide a rationale for the effect of tetracyclines and azelaic acid against rosacea. Clinically, the ROSIE group emphasized the need for a comprehensive therapy strategy \u2013 the triad of rosacea care \u2013 that integrates patient education including psychological and social aspects, skin care with dermo\u2010cosmetics as well as drug\u2010 and physical therapies. Classification of rosacea into stages or subgroups, with or without progression, remained controversial. However, the ROSIE group proposed that therapy decision making should be in accordance with a treatment algorithm based on the signs and symptoms of rosacea rather than on a prior classification.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The ROSIE group reviewed rosacea pathophysiology and medical features and the impact on patients and treatment options. The group suggested a rational, evidence\u2010based approach to treatment for the various symptoms of the condition. In daily practice this approach might be more easily handled than prior subtype classification, in particular since patients often may show clinical features of more than one subtype at the same time.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2010.03751.x","type":"journal-article","created":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T04:03:48Z","timestamp":1277438628000},"page":"188-200","source":"Crossref","is-referenced-by-count":178,"title":["Rosacea \u2013 global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group"],"prefix":"10.1111","volume":"25","author":[{"given":"BE","family":"Elewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Layton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Picardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042829"},{"key":"e_1_2_17_3_2","first-page":"1","article-title":"Systemic therapy for rosacea","volume":"12","author":"Baldwin HE","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_17_4_2","first-page":"419","article-title":"An epidemiological study of rosacea","volume":"69","author":"Berg M","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_17_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/sder.2001.27553"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0095-4543(05)70197-4"},{"key":"e_1_2_17_7_2","first-page":"1","article-title":"Prevalence of skin diseases in a population \u2013 a census study from the Faroe Islands","volume":"11","author":"Lomholt G","year":"1964","journal-title":"Dan Med Bull"},{"key":"e_1_2_17_8_2","first-page":"137","article-title":"Aetiology and pathogenesis of rosacea","volume":"30","author":"Sobye P","year":"1950","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_17_9_2","unstructured":"National Rosacea Society.Patients over 50 hardest hit with rosacea symptoms. Rosacea Review Fall. [WWW document]2000. URLhttp:\/\/www.rosacea.org\/rr\/2000\/fall\/article_2.php(last accessed: 1 July 2010)."},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000077298"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00424276"},{"key":"e_1_2_17_12_2","unstructured":"Del RossoJ.The prevalence of seborrheic dermatitis in patients with other commonly encountered facial dermatoses. Poster presentation American Academy of Dermatology summer meeting New York July 2004."},{"key":"e_1_2_17_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-59715-2_54"},{"key":"e_1_2_17_14_2","unstructured":"National Rosacea Society.14 Million Americans Have Rosacea...And Most of Them Don\u2019t Know It. [WWW document]2003. URLhttp:\/\/www.rosacea.org."},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00075.x"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1992.tb00320.x"},{"key":"e_1_2_17_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2007.50"},{"key":"e_1_2_17_19_2","first-page":"99","article-title":"Rosacea in the pediatric population","volume":"74","author":"Lacz NL","year":"2004","journal-title":"Cutis"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00890-0"},{"key":"e_1_2_17_21_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archderm.1997.03890370095014","article-title":"Ocular rosacea: current concepts and therapy","volume":"133","author":"Kligman AM","year":"1997","journal-title":"Arch Dermatol"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2003.01876.x"},{"key":"e_1_2_17_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00406420"},{"key":"e_1_2_17_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70177-2"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08028.x"},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2006.03.001"},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616"},{"key":"e_1_2_17_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.014"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2006.00695.x"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb02802.x"},{"key":"e_1_2_17_31_2","unstructured":"CameraE MastrofrancescoA IzzoEet\u00a0al.Azelaic acid counteracts the inflammatory response elicited by UVB in human keratinocytes. Presentation at 2nd International Conference \u201cSebaceous Gland Acne and Related Disorders\u201d Rome September 13\u201316 2008."},{"key":"e_1_2_17_32_2","doi-asserted-by":"crossref","unstructured":"YamasakiK GalloRL.Azelaic acid gel alters kallikrein 5 and cathelicidin expression in epidermal keratinocytes critical elements in the pathogenesis of rosacea. Presentation at the American Academy of Dermatology 68th Annual Meeting 2010; Miami; Supplement toJ Am Acad Dermatol2010;62 AB1 Poster P103.","DOI":"10.1016\/j.jaad.2009.11.041"},{"key":"e_1_2_17_33_2","first-page":"871","article-title":"Klinik, Pathogenese, Therapie","volume":"56","author":"Rosazea LP","year":"2005","journal-title":"Hautarzt"},{"key":"e_1_2_17_34_2","doi-asserted-by":"crossref","unstructured":"MillsOH RizerRL FriedRG KligmanAM TrookmanNS StoudemayerT.Rosacea: alternative approaches to research and therapy.Clin Pharmacol Ther2003;73: P4. Poster presentation at the American Academy of Dermatology Annual Meeting.","DOI":"10.1016\/S0009-9236(03)90372-9"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1444"},{"key":"e_1_2_17_36_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_17_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.084"},{"key":"e_1_2_17_38_2","first-page":"73","article-title":"The CLEAR trial: results of a large community\u2010based study of metronidazole gel in rosacea","volume":"79","author":"Wolf JE","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_17_39_2","first-page":"183","article-title":"The comparative efficacy of sodium sulfacetamide 10%\/sulphur 5% lotion and metronidazole 0.75% in the treatment of rosacea","volume":"3","author":"Lebwohl MG","year":"1995","journal-title":"J Geriatr Dermatol"},{"key":"e_1_2_17_40_2","first-page":"357","article-title":"Combination sodium sulfacetamide 10% and sulphur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea","volume":"75","author":"Torok HM","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_17_41_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639709160276"},{"key":"e_1_2_17_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1993.tb00974.x"},{"issue":"6","key":"e_1_2_17_43_2","first-page":"11","article-title":"Photographic evidence from a clinical study comparing benzoyl peroxide 5%\/clindamycin 1% topical gel with vehicle in the treatment of rosacea","volume":"73","author":"Leyden JJ","year":"2004","journal-title":"Cutis"},{"key":"e_1_2_17_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb04533.x"},{"key":"e_1_2_17_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690030051008"},{"key":"e_1_2_17_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02130.x"},{"key":"e_1_2_17_47_2","first-page":"94","article-title":"Topical metronidazole: a new therapy for rosacea","volume":"9","author":"Schmadel LK","year":"1990","journal-title":"Clin Pharm"},{"key":"e_1_2_17_48_2","unstructured":"BeutnerK CalvareseB GraeberM.A multi\u2010center investigator\u2010blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. Presented at: American Academy of Dermatology 63rd Annual Meeting 2005; New Orleans P101."},{"key":"e_1_2_17_49_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001030-00007"},{"key":"e_1_2_17_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub3"},{"key":"e_1_2_17_51_2","first-page":"559","article-title":"Cutaneous tolerability of metronidazole topical gel 0.75% for rosacea","volume":"18","author":"Del Rosso JQ","year":"2005","journal-title":"Cos Dermatol"},{"key":"e_1_2_17_52_2","first-page":"271","article-title":"A status report on medical management of rosacea: focus on topical therapies","volume":"70","author":"Del Rosso JQ","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_17_53_2","first-page":"317","article-title":"Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter?","volume":"5","author":"Yoo J","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_17_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02849891"},{"key":"e_1_2_17_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01914.x"},{"key":"e_1_2_17_56_2","doi-asserted-by":"publisher","DOI":"10.3109\/10715769109049121"},{"key":"e_1_2_17_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00372056"},{"issue":"5","key":"e_1_2_17_58_2","first-page":"6","article-title":"Azelaic acid gel 15%: clinical versatility in the treatment of rosacea","volume":"78","author":"Del Rosso JQ","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_17_59_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247303"},{"key":"e_1_2_17_60_2","first-page":"125","article-title":"Facial seborrheic dermatitis: a report on current status and therapeutic horizons","volume":"8","author":"Bikowski J","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_17_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02283.x"},{"key":"e_1_2_17_62_2","unstructured":"GoldM FarberH GilboaR TschenE.Use of benzoyl peroxide\/clindamycin gel in the once daily treatment of moderate rosacea. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18\u201322 2005; New Orleans LA. Poster P161"},{"key":"e_1_2_17_63_2","first-page":"83","article-title":"A lifetime of healthy skin: implications for women","volume":"44","author":"Bergfeld WF","year":"1999","journal-title":"Int J Fertil"},{"key":"e_1_2_17_64_2","first-page":"89","article-title":"The effect of local administration of corticosteroids on the course and therapy of rosacea","volume":"111","author":"Basta\u2010Juzbasic A","year":"1989","journal-title":"Lijec Vjesn"},{"key":"e_1_2_17_65_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00641.x"},{"key":"e_1_2_17_66_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_2_17_67_2","first-page":"1782","article-title":"Permethrin cream useful in the treatment of rosacea","volume":"67","author":"Slawson D","year":"2003","journal-title":"Am Fam Physician"},{"key":"e_1_2_17_68_2","first-page":"251","article-title":"Rosacea: where are we now?","volume":"3","author":"Bikowski JB","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_17_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02157-1"},{"key":"e_1_2_17_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.11.1369"},{"issue":"4","key":"e_1_2_17_71_2","first-page":"3","article-title":"Efficacy and safety of once\u2010daily metronidazole 1% gel compared with twice\u2010daily azelaic acid 15% gel in the treatment of rosacea","volume":"77","author":"Wolf JE","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_17_72_2","first-page":"927","article-title":"Tetracycline suppresses matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage","volume":"19","author":"Greenwald R","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_17_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1966.tb12168.x"},{"key":"e_1_2_17_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)90376-X"},{"key":"e_1_2_17_75_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.66.6.386"},{"key":"e_1_2_17_76_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.1.1025697"},{"key":"e_1_2_17_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_2_17_78_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.6.679"},{"key":"e_1_2_17_79_2","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy","volume":"8","author":"Thiboutot DM","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_17_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.010"},{"key":"e_1_2_17_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2005.10.026"},{"key":"e_1_2_17_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31204"},{"key":"e_1_2_17_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01472.x"},{"key":"e_1_2_17_84_2","unstructured":"GollnickH.Optimal Isotretinoin Dosing for Rosacea 18th Congress of the European Academy of Dermatology and Venereology Berlin 2009."},{"key":"e_1_2_17_85_2","first-page":"269","article-title":"Surgical treatment of rhinophyma","volume":"37","author":"Kilty S","year":"2008","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"e_1_2_17_86_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/120347549900300403","article-title":"Needs survey of Canadian rosacea patients","volume":"3","author":"Shear N","year":"1999","journal-title":"J Cutan Med Surg"},{"key":"e_1_2_17_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2006.00174.x"},{"key":"e_1_2_17_88_2","first-page":"577","article-title":"Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases","volume":"12","author":"Boehncke WH","year":"2002","journal-title":"Eur J Dermatol"},{"key":"e_1_2_17_89_2","first-page":"344","article-title":"Effective sunscreen ingredients and cutaneous irritation in patients with rosacea","volume":"61","author":"Nichols K","year":"1998","journal-title":"Cutis"},{"key":"e_1_2_17_90_2","first-page":"997","article-title":"Psychosocial impact of rosacea","volume":"64","author":"Chodkiewicz J","year":"2007","journal-title":"Przegl Lek"},{"key":"e_1_2_17_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.048"},{"key":"e_1_2_17_92_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02371.x"},{"key":"e_1_2_17_93_2","volume-title":"Coping with Rosacea. Tips on Lifestyle Managment for Rosacea Sufferers","author":"National Rosacea Society","year":"1996"},{"issue":"1","key":"e_1_2_17_94_2","first-page":"49","article-title":"Role of psychological factors in course of the rosacea","volume":"50","author":"Sowi\u0144ska\u2010G\u0142ugiewicz I","year":"2005","journal-title":"Rocz Akad Med Bialymst"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2010.03751.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2010.03751.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T02:50:59Z","timestamp":1697338259000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2010.03751.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,4]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1468-3083.2010.03751.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03751.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,4]]}}}